BL AMERICAN SMALL & MID CAPS


May 2025




BLI - Banque de Luxembourg Investments



Who are we?



Employee Breakdown by Departments





 Management company of Banque de Luxembourg operating under two distinct brands

- BLI: Investment Management
- Conventum TPS: Third Party Management Company
- → € 16,2 bn AUM as of end of May 2025, with
 € 12,2 bn directly managed by BLI
- Strong corporate culture linked to our private banking heritage:
 - We stress human values, integrity and collegiality,
 - Culture of independent thinking and passion for investing,
 - Focus on our sphere of competence: "common sense for a complex world",
 - Conviction-based investment approach centred on the generation of attractive long-term risk adjusted returns.

69 employees of whom 25 are investment professionals with long company tenure,

→ Investment team located in Luxembourg, away from the noise of major financial centres.

BLI - Banque de Luxembourg Investments

→ Corporate Structure

INVESTMENTS

\rightarrow Organisation chart



BLI - Banque de Luxembourg Investments

An investment philosophy common to all equity strategies



Henrik Blohm, Lead Fund Manager

- Degree in Business studies (University of Innsbruck and San Diego State University) with a specialization in Banking and Finance,
- Professional experience since 07/2010,
- Joined BLI in 07/2014,
- In charge of American Small & Mid Cap strategies since 11/2015.

Julien Jonas, Analyst

- Degree in Economics, University of Vienna (Austria)
- Joined BLI in 05/2017
- SRI Strategist from 2019 to March 2022
- US Equity Analyst since 04/2022

Guy Wagner, CIO, Manager	
European equities Ivan Bouillot, Manager All caps Family-owned companies Tom Michels, Manager Small & Mid-caps Amélie Morel, Analyst All caps	US equities Henrik Blohm, Manager • Small & Mid-caps Julien Jonas, Analyst • All caps Luc Bauler, Manager • Large caps
Japanese and emerging equities Steve Glod, Manager Japan, all caps Marc Erpelding, Manager Asia excl. Japan LatAm & EEMOA Raphaël Fürst, Analyst Asia incl. Japan	Global equities Maxime Hoss, Manager All caps Jérémie Fastnacht, Manager Dividends Annick Drui, Manager SRI

SRI Strategy & Stewardship Thierry Feltgen Alice Tharaud Misch Koob Hongxin Chen




(4

INVESTMENT CASE AMERICAN SMALL & MID CAPS



High exposure to the world's largest and most dynamic economy






Source Bloomberg: Small caps stocks are represented by the Russell 2000 Index. Mid cap stocks are represented by the Russell Midcap Index. Large cap stocks are represented by the S&P 500 Index; Based on fiscal-year 2022 revenues.

Investors are often underexposed to Mid and Small Caps

Mid caps make up 23% of US equity market cap but only 10% of US equity investor assets.




Source FactSet and Morningstar, as of 31/12/2023




Companies in the most attractive stage of their life cycle

→ Once through the difficult start-up phase, Small & Mid cap companies enter the phase where they can deploy all their growth potential



Mid Cap companies show an attractive risk-adjusted return profile

Note: Past performance does not guarantee or predict future performance.




Source Morningstar 31/12/2023

Mid Caps: Russell MidCap Index; Large Caps: Russell 1000 Index; Small Caps: Russell 2000 Index Past Performance does not guarantee or predict future performance

BLI BANQUE DE LUXEMBOURG INVESTMENTS

Significant long-term outperformance of Mid Caps vs. Small and Large Caps

Note: Past performance does not guarantee or predict future performance.



Source Bloomberg 29/12/2023


Large Caps: Russell 1000 Index; Mid Caps: Russell MidCap Index; Small Caps: Russell 2000 Index

Past performance does not guarantee or predict future performance



A high quality and growth approach has led to strong historical performance in Mid Caps

Note: Past performance does not guarantee or predict future performance.




Source Ned Davis Research (NDR), 31/12/23. The NDR Mid-Cap Index is a proprietary index designed to measure the performance of mid-sized company stocks in the United States. Return on Invested Capital (ROIC) is a measure of quality that measures the percentage return of profitability earned by a company using the capital invested by equity and debt providers. The performance shown is a hypothetical investment of \$100 in each of the categories.



Under-researched market segment

The Smaller Cap universe offers ample opportunities for active managers since it is less well researched than large cap indices.



Mean Analyst Coverage by Capitalisation Range




INVESTMENT APPROACH



2

Investment Approach

Philosophy






Investment Approach

Risk consciousness at the heart of the process ...

<u>Note</u>: Performance net of fees. Past performance does not guarantee or predict future performance. Reference to a market index is made for comparison purposes only; the market index is not mentioned in the investment policy of the sub-fund.



... leads to an attractive risk/return profile.

Data in USD as of 30/5/2025

Source: Lipper/BLI.


*Peer Group Average: The average of the fund's Lipper peer group, minus the funds not registered for sale in the following countries: Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, Netherlands, Norway, Singapore, Spain, Sweden, Switzerland, UK.



INVESTMENT PROCESS



Bottom-up investment process





A multi-pillar ESG approach

PRE INVESTMENT


Exclusions (BLI's general policy):

- \rightarrow Companies
- Active in the production of controversial weapons
- Included in the Global Coal Exit List
- \rightarrow Companies not complying with the Principles of the **UN Global Compact** (*)
- \rightarrow Companies involved in **highly** severe controversies (red flag) (*)

INTRA INVESTMENT

ESG Integration

- \rightarrow Integration of ESG factors in the valuation process
- Increase / Reduction of Cost of equity depending on ESG rating (*)



POST INVESTMENT

Voting policy

→ As an active investor, BLI votes at the annual meetings of invested companies

Engagement policy


- → BLI initiates an active engagement policy with invested companies.
- \rightarrow Focus is on defined impact factors as well as wider ESG topics.

Controversies follow-up: Ongoing monitoring of analysed controversies to assess realised progress

(*) ESG ratings and data are sourced from the specialised MSCI ESG Manager database



Different sources of investment ideas





Business Model Differentiation

Intangible Assets	Customer Captivity	Network	Cost Advantage	Technology & Know-How
Brand Perceived Quality	Switching Costs Aftermarket Sales Ongoing Service	Network Effect Distribution Network	Lower Costs Economies of Scale	Proprietary Technology Innovation Patents
Ettelfuse Ettelfuse	Jack henry Associates INC tyler tyler tyler technologies Verisk LABORATORIES			Bentley ResMed


⇒ No long-term success without competitive advantage




Fundamental Analysis

- Qualitative assessment of the company's competitive advantage(s)
- → Quantitative evidence of an economic moat
 - Economic profit levels (ROCE, ROE)
 - Operating Margins
- → Analyse additional company fundamentals
 - Balance sheet strength
 - Capital Intensity
 - Quality of management
- → Assess the company's ESG profile (MSCI ESG Score)
- \rightarrow Assess the company's FCF-generation capacity
- → Identify the company's secular growth drivers
 - Favourable industry trends
 - Innovation capacity

⇒ No profitable growth without competitive advantage







Valuation Model*

 \rightarrow Get an indication about the value of the company without future growth

- Calculation of the Earnings Power Value EPV (the value of the company based on its current business using adjusted FCF)
- → Future growth only creates value if the company benefits from a sustainable competitive advantage
 - Calculation of the growth-related value multiplier GM and the fair value of the company FV




⇒ Provide a reference point to avoid overpaying for quality companies

*Bruce Greenwald et al. (2001). "Value Investing: From Graham to Buffett and beyond", Wiley Finance



Valuation Model




⇒ Integration of several risk factors into the cost of capital that is used in the valuation model




Portfolio Construction

→ Investments are initiated with a discount (margin of safety) to the fair-value



 \rightarrow Investment weightings depend on the following factors:



→ Stocks are sold when the investment thesis fundamentally weakens, the growth profile deteriorates, valuation becomes excessive or better investment opportunities arise



Portfolio Structure

GF Growing Franchises	CE Consistent Earners	EV Established Value		
Focus on GROWTH	Focus on CONSISTENCY	Focus on VALUE		
Strong-growth business model	Stable business model	Challenged business model		
50 - 75 % of portfolio	20 - 40 % of portfolio	0 - 15 % of portfolio		
Buy discipline : below FV	Buy discipline : >~5 % discount to FV	Buy discipline : >~20 % discount to FV		
Prime reasons to sell : 1. Growth ? 2. Thesis	Prime reasons to sell : 1. Thesis 2. Valuation	Prime reasons to sell : 1. Valuation 2. Thesis		
Expected turnover rate: Medium	Expected turnover rate: Low	Expected turnover rate: High		

⇒ Diversified sources of alpha



PORTFOLIO CHARACTERISTICS



Portfolio Characteristics

BL American Small & Mid Caps

- → The portfolio invests in 40 to 60 American Small & Mid cap companies, with a maximum market cap of USD 30 bn
- → **Pure bottom-up** investment approach, with no top-down decisions
- → Sector allocation is not linked to a benchmark it results from individual investment opportunities
 - Quality companies are predominantly from the consumer, industry, healthcare and technology sectors
 - Limited to no exposure to Real Estate, Financials, Telecoms, Energy or Utilities
 - As a result, the portfolio structure can deviate significantly from the benchmark
- \rightarrow The quality approach leads to a structural bias towards mid-caps
- → Portfolio volatility typically lower than market volatility
- → Lower risk through portfolio construction by combining stable growth with higher growth stocks
- \rightarrow Low turnover strategy, aligned with our long-term investment approach.

	2017	2018	2019	2020	2021	2022	2023	2024
Portfolio Turnover Rate*	24%	33%	17%	22%	18%	14%	14%	29%

 \rightarrow The cash level is usually maintained at a minimum (**no market timing**)




PORTFOLIO REVIEW



5

Top Holdings

Idexx Laboratories	4,6%
Verisk Analytics	4,2%
Resmed	3,9%
Siteone Landscape Supply	3,4%
Jack Henry + Associates	3,3%
Paycom Software	3,3%
Check Point Software Technologies	3,0%
Bentley Systems Inc	2,9%
Equifax	2,6%
Chemed	2,6%
Core & Main Inc	2,6%
Verisign Inc	2,6%
Graco	2,5%
Masimo Corp	2,5%
Pool	2,4%
# holdings	43
Cash	0,96%
Weight top 10 holdings	34,0%
Weight top 20 holdings	58,0%



Cash

69,3%

Data as of 30/5/2025



Holding changes over one-year period








Since launch (Nov. 2015) ten companies have been acquired

→ The financial strength and growth characteristics of some small and mid-cap companies make them attractive acquisition targets.

		Amplify Snack Brands							
	Whitewave	C.R. Bard	Blue Buffalo Pet Products						
	Valspar	Mead Johnson Nutrition	Dr Pepper Snapple			NIC	AspenTech		Ansys
Calendar Year	2016	2017	2018	2019	2020	2021	2022	2023	2024



Sector Allocation vs Index




Data source: MSCI / BLI

Data is given as information only and is as a given date and may evolve over time. Reference to a market index is made for comparison purposes only; the market index is not mentioned in the investment policy of the sub-fund.



Historic Sector Allocation




Data as of 30/5/2025

Each bar in the graph represents one month Source: MSCI / BLI



Market Cap Allocation vs Benchmark



Data as of 30/5/2025

Data source: MSCI / BLI

Data is given as information only and is as a given date and may evolve over time. Reference to a market index is made for comparison purposes only; the market index is not mentioned in the investment policy of the sub-fund.



CASE STUDIES



6




ResMed is a **leading developer and manufacturer of medical devices, masks and cloud-based software applications** that diagnose, treat, and manage sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions

A proven global leader in underpenetrated and attractive markets

INVESTMENT CASE

- ResMed operates in a oligopolistic market
- 26% of adults have some form of obstructive sleep apnea
- Sleep apnea market is large, underpenetrated and underdiagnosed
- Greater awareness and more convenient testing options should lead to increased penetration
- Demographic trends (especially ageing and obesity)
- Leader in innovating new products to improve patient outcomes
- Connected devices help cement its market leading position
- Highly profitable recurring revenue stream through masks and accessories
- Additional opportunities in respiratory care
- More than 380mn people worldwide are estimated to have a Chronic Obstructive Pulmonary Disease (COPD) and is the third leading cause of death
- Reduces Healthcare system costs by preventing hospitalization







Sleep Heart Health Study: 26% of adults have sleep apnea



36

IDEXX Laboratories serves veterinarians around the world with an integrated portfolio of diagnostic and information technology-based products and services (88% of sales). Aside from companion animal diagnostics, the company also offers livestock and water diagnostic solutions.

The undisputed leader in the highly attractive companion animal diagnostics market

INVESTMENT CASE

- Global leadership in a very profitable veterinarian diagnostic market
- Only player with significant capabilities in both POC (tests in vet's office) and reference labs
- Best-in-class reputation and product offering (Considered by veterinarians as the "gold standard")
- Secular trend of increased pet ownership and humanization of pets
- Pet owners spending outpaces consumer growth
- IDEXX has demonstrated resilience in times of economic uncertainty
- Lab Diagnostics as a percent of vet practice revenue is increasing
- Recurring high margin revenue streams with strong customer retention rates
- Strong track record of innovative new test introductions
- Interesting lineup of new products
- Long-term, durable 10%+ organic growth potential with high ROIC



IDEXX Fully-integrated Multi-modality Diagnostic and Software Solutions Raise Standards of Care


Intangible

Assets




High Customer Retention Enables Our Durable CAG Recurring Annuity

Annual U.S. Customer Revenue Retention Rates







GF

Technology/

Know-How

PERFORMANCE REVIEW

Past performance does not guarantee or predict future performance. References to a market index are made for comparison purposes only; the market index is not mentioned in the investment policy of the sub-fund.



Performance vs Index Since Launch




Data in USD as of 30/5/2025

Data source: Lipper / MSCI / BLI Performance net of fees.



Annual Performance



Data in USD as of 30/5/2025

Data source: Lipper / MSCI / BLI Performance net of fees.



6 months

Ranking

6 months	Performance	Volatility*
BL American Small & Mid Caps B	-7,0%	17,4%
Lipper Global Equity US Small & Mid Cap	-11,3%	20,9%
MSCI US Small + Mid Cap NR	-9,5%	22,1%
Quartile	1	1
Ranking	10 / 89	4 / 89
1 year	Performance	Volatility*
BL American Small & Mid Caps B	2,6%	16,3%
Lipper Global Equity US Small & Mid Cap	2,5%	20,1%
MSCI US Small + Mid Cap NR	6,7%	20,4%
Quartile	2	1
Ranking	24 / 86	4 / 86
3 years	Performance	Volatility*
BL American Small & Mid Caps B	17,0%	18,3%
Lipper Global Equity US Small & Mid Cap	19,2%	19,7%
MSCI US Small + Mid Cap NR	22,5%	20,3%
Quartile	2	1
Ranking	36 / 76	5 / 76
5 years	Performance	Volatility*
BL American Small & Mid Caps B	45,2%	17,9%
Lipper Global Equity US Small & Mid Cap	67,0%	19,5%
MSCI US Small + Mid Cap NR	76,4%	19,8%
Quartile	3	1
Ranking	42 / 66	6 / 66
Since Launch **	Performance	Volatility*
BL American Small & Mid Caps B	146,3%	17,5%
Lipper Global Equity US Small & Mid Cap	116,5%	20,3%
MSCI US Small + Mid Cap NR	140,1%	20,8%
Quartile	1	1
Ranking	9 / 44	1 / 44

Performance


Data in USD as of 30/5/2025

Volatilitv*

* Annualised ** 16/11/2015 Data source: Lipper / MSCI / BLI Performance net of fees.



Scatter Chart vs. Peergroup




Data in USD as of 30/5/2025

*Peer Group Average: The average of Lipper Global Equity US Sm&Mid Cap peer group, minus the funds not registered for sale in the following countries: Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, Netherlands, Norway, Singapore, Spain, Sweden, Switzerland, UK. Data source: Lipper / BLI Performance net of fees.



Bull / Bear Profile by Market Phases



BL American Small & Mid Caps B vs. MSCI US Small + Mid Cap 2200 NR

Data in USD as of 30/5/2025

Monthly data since launch (13/11/2015) Data source: Lipper / BLI Performance net of fees.



Comparison since launch...

	BL American Small & Mid Caps B	Lipper Global Equity US Small & Mid Cap ¹	Decile ²
Volatility	17,5%	20,3%	1
Sharpe Ratio	0,51	0,39	1
Sortino Ratio	0,48	0,37	1
Max Drawdown	-28,9%	-38,7%	1

Data in USD as of 30/5/2025

Source Lipper ¹average of the funds with same track record ²Lower = Better Performance net of fees.

→Lowest volatility in the peer group

→Strong risk-adjusted return profile

→Lowest maximum drawdown



SUMMARY



8

Summary

- → BL American Small & Mid Caps focuses on the "Sweet Spot" of the US market investing in faster growing, high-quality and predominantly mid-cap companies
- → Targets high-return businesses that are able to protect their returns against competition
- \rightarrow Where growth is driven from reinvestment of their cash flows at high rates of return

High-quality companies that are compounding value over time.

- \rightarrow Use of an in-house valuation model to avoid overpaying
- → Risk managed by combining consistent earners with higher growth stocks

BL American Small & Mid Caps generates attractive risk adjusted returns







Operational Data

Opportunities & Risks

Opportunities

- American small-and mid-cap stocks exhibiting a favourable growth dynamic
- Active, bottom-up, conviction-driven management approach geared towards the long term
- Emphasis on high-quality growth companies
- Structural bias in favour of mid-cap stocks
- Defensive growth profile

Risk profile

- Currency risk. The Fund's currency may differ from your reference currency, in which case the final return will depend on the exchange rate between the two currencies. This risk is not taken into account in the indicators shown above;
- The sub-fund may also be exposed to other significant risks, which are not included in the synthetic risk indicator: liquidity risk.
- As this product provides no protection against market fluctuations, you could lose your entire investment.



48

Operational Data

BL American Small & Mid Caps									
Fund Volume (overall)	\$ 556,7 mn								
Launch Date	13/11/2015								
SFDR	Art. 8								
Currency	USD	USD	EUR	USD	USD	EUR	USD	EUR	
Share class	А	В	B Eur Hedged	AM	BM	BM Eur Hedged	BI	BI Eur Hedged	
Investor type	Retail	Retail	Retail	Retail ²	Retail ²	Retail ²	Institutional ²	Institutional ²	
Cap/Dis	Dis	Сар	Сар	Dis	Сар	Сар	Сар	Сар	
Management fee	1,25%	1,25%	1,25%	0,85%	0,85%	0,85%	0,60%	0,60%	
Ongoing charges	1,48%	1,44%	1,42%	1,13%	1,06%	1,03%	0,74%	0,73%	
Turnover (2024) ¹	28,49%								
ISIN	LU1484763229	LU1305478775	LU1305478932	LU1484763575	LU1484763658	LU1484763732	LU1484763815	LU1867116706	
WKN	A2ARBP	A1421A	A1421B	A2ARBQ	A2ARBR	A2ARBS	A2ARBT	A2N62S	
Bloomberg	BLEFBAU LX	BLAMSCB LX	BLASBEH LX	BLASCAM LX	BLASCBM LX	BLASBME LX	BLASCBI LX	BLASBIH LX	
Countries registered for sale	Austria, Belgium, Denmark, Finland, France, Germany (tax transparent), Italy, Luxembourg, Netherlands, Norway, Portugal, Singapore ³ , Spain, Sweden, Switzerland, UK								

¹ min (purchases, sales) / average of net assets
 ² Eligibility criteria according to Prospectus SICAV BL
 ³ under restricted scheme



Contact Details

BLI BANQUE DE LUXEMBOURG INVESTMENTS

16, boulevard Royal –L-2449 Luxembourg
Tel.: (+352) 26 26 99 –1
E-Mail: business-support@bli.lu
Coverage: Professional & institutional clients, all regions



14, boulevard Royal –L-2449 Luxembourg Tel.: (+352) 49 924 –1 E-Mail: info@bdl.lu Coverage: Private clients, all regions





Kungsgatan10 –SE-111 43 Stockholm **Tel.:** (+46) 8 660 80 40 **E-Mail:** intervalor@intervalor.com **Coverage:** Professional & institutional clients, Nordics

LA FRANÇAISE

→ Paris Office:

128, Boulevard Raspail–F-75006 Paris Tel.: (+33) (0) 1 73 00 73 00 E-Mail: Iffsclientservices@la-francaise.com

→ Luxembourg Office:

16, boulevard Royal –L-2449 Luxembourg E-Mail: Iffsclientservices@la-francaise.com

Coverage: Professional & institutional clients, all regions

Legal information

This document has been drawn up by BLI - Banque de Luxembourg Investments ("**BLI**") and is **intended solely for professional investors**. It refers directly or indirectly to one or more financial products (the "**Financial Product**") and constitutes a marketing communication within the meaning of Regulation (EU) 2019/1156 of 20 June 2019 on facilitating cross-border distribution of collective investment undertakings.

The economic, financial and non-financial information contained in this document (the "Information") is provided on the basis of the information known at the date of publication and is subject to change without notice. The Information originates (in whole or in part) from sources external to BLI or is based on such sources. BLI believes it has taken reasonable measures to ensure that the Information is accurate and up-to-date as of the date of this document. However, BLI cannot guarantee the accuracy and/or timeliness of the Information.

The Information does not constitute investment advice, an invitation to invest in the Financial Product, or legal or tax advice. All recipients of this document should be aware that:

- All investments in the Financial Product entail specific risks, which are detailed in the issue document and in the Key Information Document of the Financial Product.
- The past performance of the Financial Product is no guarantee of its future performance. The value of the Financial Product and the income derived from it may rise or fall and investors may not recover their initial investment.
- Any performance data presented in this document does not take into account any commissions, fees or taxes incurred in connection with the subscription or redemption of units in the Financial Product.
- The Financial Product is not managed by reference to a benchmark index.

In general, BLI assumes no responsibility for the future performance of any Financial Product. BLI cannot be held liable for any decisions that a recipient of this document may or may not make on the basis of the Information. Individuals interested in investing in a Financial Product must ensure the suitability of such an investment for their personal situation and seek independent advice, if needed or in case of doubt. They must also consider the characteristics and objectives of the Financial Product, in particular where reference is made to sustainability-related aspects in accordance with Regulation (EU) 2019/2088 of the European Parliament and of the Council of 27 November 2019 on sustainability-related disclosures in the financial services sector. This Information is available on BLI's website at www.bli.lu.



Legal information

Investment in the Financial Product may only be made on the basis of the issue document, the Key Information Document and the most recent annual report or semi-annual report of the Financial Product; these documents are in each case in the version in force at the time the investment decision is made (the "**Documents**"). The Documents are available free of charge upon request by post addressed to BLI – Banque de Luxembourg Investments, 16, boulevard Royal, L-2449 Luxembourg or by e-mail addressed to info@bli.lu. BLI can also indicate the languages in which each Document is available.

Individuals interested in investing in the Financial Product are informed that a summary of their investor rights is available on BLI's website at:

https://www.banquedeluxembourginvestments.com/en/bank/bli/legal-information

Finally, BLI wishes to emphasise that it may decide at any time to cease marketing the Financial Product, subject to compliance with the applicable legal and regulatory provisions.

This document may not be reproduced, in whole or in part, without the prior written consent of BLI.

BLI - Banque de Luxembourg Investments, a management company approved by the *Commission de Surveillance du Secteur Financier Luxembourg (CSSF)*16, boulevard Royal
L-2449 Luxembourg
RCS number: B80479.



Specific Information concerning MSCI Data:

All MSCI data is provided "as is". Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the result to be obtained by the use thereof) and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in or related to compiling, computing or creating the data have any liability for any direct, indirect, special punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI's express written consent.

Specific Information concerning GICS Data:

The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of MSCI Inc. ("MSCI") and Standard and Poor's, a division of The McGraw-Hill Companies, Inc. ("S&P") and is licensed to use by Banque de Luxembourg S.A.. Neither MSCI, S&P nor any third party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classification have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if noticed of the possibility of such damages.

